AXSM
Axsome Therapeutics Inc
173.00$
-0.8%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1,661.3% | -22.1% | -7.0% | -56.7% | +1,334.1% | -15.6% | -52.8% | +277.6% | +77.5% | -3.4% | +21.3% | |
| – | +1,687.1% | -22.5% | -7.1% | -56.9% | +1,348.4% | -16.5% | -53.0% | +183.9% | +105.3% | -3.8% | +21.4% | |
| – | +1,735.0% | -23.8% | -7.1% | -58.9% | +1,474.7% | -16.4% | -53.0% | +132.3% | +92.3% | -18.3% | +2.4% | |
| – | +1,735.0% | -23.8% | -7.1% | -58.9% | +1,474.7% | -16.4% | -53.0% | +132.3% | +92.3% | -18.3% | +2.4% | |
| – | – | – | – | – | – | – | – | – | +151.5% | +49.8% | +58.1% | |
| – | – | – | – | – | – | – | – | – | +250.3% | +3.9% | +77.6% | |
| – | – | +504.9% | -32.4% | -23.9% | -40.9% | +71.9% | +439.1% | +302.6% | – | – | – | |
| – | – | – | – | – | – | – | – | – | +16.8% | +0.0% | +0.0% | |
| – | – | – | – | – | – | – | – | – | -10.7% | -12.0% | -13.6% | |
| – | -56.1% | +532.3% | +13.2% | -23.3% | +189.6% | +73.0% | -0.3% | +207.6% | +79.0% | +28.8% | +17.6% | |
| – | +170.6% | +172.5% | +69.8% | -11.1% | +126.3% | -4.3% | -1.6% | +318.6% | +43.8% | +65.7% | +64.6% | |
| – | – | – | +1,114.6% | +0.7% | -20.9% | -53.1% | -49.1% | -31.5% | +198.1% | +157.0% | +2,141.4% | |
| – | +149.6% | +115.7% | -15.8% | +7.3% | +196.8% | +23.4% | -2.6% | +193.6% | +5.4% | +77.0% | -9.0% | |
| – | – | – | -29.6% | -45.7% | +378.9% | +178.8% | +1.6% | +92.0% | +88.9% | +1.5% | -34.8% | |
| – | – | -53.6% | -22.5% | -94.4% | +18,955.2% | -36.3% | -86.3% | +600.9% | +74.3% | -70.1% | +54.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -6.1% | +60.3% | +18.9% | +18.1% | +26.5% | +9.4% | +1.1% | +8.1% | +11.7% | +5.5% | +3.8% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.